What is Mounjaro and how does the weight-loss jab work? Pharmacies to face stricter checks for popular drug - Pharmacists who ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

B, consensus $58.91B. The company said, “The company anticipates 2025 revenue to be between $58.0 billion and $61.0 ...

Pharmacy regulator warns some people with history of eating disorders wrongly obtaining medicines such as Wegovy or Mounjaro ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Pharmacy regulator warns some people with history of eating disorders wrongly obtaining medicines such as Wegovy or Mounjaro ...

Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to make changes to prevent people from receiving drugs that could cause them ...

while Mounjaro (tirzepatide), a product of competitor Eli Lilly (NYSE:LLY), saw 469,180 weekly prescriptions. The company has also made strides in expanding indications for its existing products.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.